Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
23 hours ago
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.

Current smoking ups death, hospitalization in HFpEF patients

12 Sep 2018

Current smoking increases the likelihood of adverse outcomes in patients with heart failure with preserved ejection fraction (HFpEF), a recent study has shown.

Researchers analysed 1,717 patients with HFpEF (mean age 71±10 years; 50 percent male), most of whom (51 percent; n=871) were former smokers. Seven percent (n=116) and 42 percent (n=729) were current and never smokers, respectively.

Over a median follow-up period of 2.9 years, researchers observed 387 hospitalizations for heart failure. Cox regression analysis showed that compared with former smokers, current smokers were significantly more likely to be hospitalized for heart failure (hazard ratio [HR], 1.68; 95 percent CI, 1.08–2.61; p=0.02).

In the same time span, there were 374 deaths recorded, majority of which (n=218) were cardiovascular in nature. Relative to never smoking, current smoking was likewise associated with significantly higher risks of death (HR, 1.82; 1.19–2.78; p=0.0057) and cardiovascular death (HR, 1.85; 1.09–3.14; p=0.022).

No such effect was observed for former smoking compared with never smoking (hospitalization for heart failure: HR, 1.25; 0.99–1.57; p=0.053; death: HR, 1.02; 0.81–1.29; p=0.85; cardiovascular death: HR, 1.00; 0.74–1.35; p=0.99).

Analyses were adjusted for age, sex, race, body mass index, aspirin and antihypertensive medication use, systolic blood pressure, and comorbidities such as diabetes, chronic obstructive pulmonary disease, stroke and coronary heart disease.

Though further studies are needed to confirm these findings, the present results suggest that smoking cessation programmes may be beneficial to HFpEF patients, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
23 hours ago
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.